摘要
目的 :观察罗格列酮与格列齐特联合治疗 2型糖尿病的临床疗效。方法 :将 64例接受格列齐特治疗的 2型糖尿病患者分为治疗组和对照组。治疗组 (n =3 0 )在服用格列齐特的基础上 ,予罗格列酮 4mg·d-1,12wk。对照组保持原治疗。分别测定用药前后体重、空腹血糖 (FBG)、空腹胰岛素 (FIN)、糖化血红蛋白 (HbA1C)、血脂及肝、肾功能等。结果 :治疗组治疗后FBG降低 2 3 6% ,对照组降低 7 8% ;治疗组治疗后FIN降低 13 4% ,对照组上升 3 4% ;治疗组治疗后HbA1C下降 2 5 4% ,对照组下降 3 6% ;治疗组治疗后TG下降 3 0 9% ,对照组下降 3 2 % ;治疗组治疗后HDL C水平上升 16 7% ,对照组HDL C水平上升 1 8%。结论 :罗格列酮不仅能降低 2型糖尿病血糖水平 ,而且能提高 2型糖尿病患者的胰岛素敏感性 。
AIM: To evaluate the efficacy of rosiglitazone in the treatment of type 2 diabetes mellitus. METHODS: Sixty-four type 2 diabetic patients were randomly assigned to therapy group or control group, respectively. All of them were measured weight, fasting blood glucose (FBG), fasting serum insulin (FIN), blood lipid spectrum, HbA 1C, liver and kidney function before and after treatment. RESULTS: After treatment, FBG in therapy group and control group decreased 23.6% and 7.8%; HbA 1C in therapy group and control group decreased 25.4% and 3.6%; triglycerides (TG) in therapy group and control group decreased 30.9% and 3.2%; high-density lipoprotein cholesrerol (HDL-C) in therapy group and control group increased 16.7% and 1.8%, respectively. CONCLUSION: Rosiglitazone not only can decrease the blood glucose of type 2 diabetes mellitus, but also can improve the insulin sensitivity of type 2 diabetes mellitus. It also shows effects on the blood lipid.
出处
《中国临床药学杂志》
CAS
2003年第3期144-146,共3页
Chinese Journal of Clinical Pharmacy
